VIVREON BIOSCIENCES LLC
San Diego, CA · Biotech · Private
Small molecule therapeutic that prevents opioid-induced microglial inflammation to block opioid dependence development
- Grants
- $19M
- 34 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 1 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $222,453 | |
| Federal grant | Department of Health and Human Services · Phase I · Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $222,453 | |
| Federal grant | Department of Health and Human Services · Phase I · Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, for the Treatment of Ulcerative Colitis | $219,975 | |
| Federal grant | Department of Health and Human Services · Phase I · Predevelopment of VV a Novel CRAC Channel Inhibitor for the Treatment of Ulcerative Colitis | $219,975 | |
| Federal grant | Department of Health and Human Services · Phase II · Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $746,325 | |
| Federal grant | Department of Health and Human Services · Phase I · Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $745,976 | |
| Federal grant | Department of Health and Human Services · Phase II · Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $1,250,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $270,902 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $270,902 | |
| Federal grant | Department of Health and Human Services · Phase II · Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | $1,004,278 | |
| Federal grant | Department of Health and Human Services · Phase II · Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | $224,700 | |
| Federal grant | Department of Health and Human Services · Phase II · Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $1,249,999 | |
| Federal grant | Department of Health and Human Services · Phase II · Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | $249,806 | |
| Federal grant | Department of Health and Human Services · Phase I · Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder | $404,967 | |
| Federal grant | Department of Health and Human Services · Phase I · Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder | $349,967 | |
| Federal grant | Department of Health and Human Services · Phase II · Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $193,392 | |
| Federal grant | Department of Health and Human Services · Phase I · Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder | $55,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Predevelopment of VV8321, a Novel CRAC Channel Therapeutic for the Treatment of Osteoarthritis | $252,039 | |
| Federal grant | Department of Health and Human Services · Phase I · Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis | $299,989 | |
| Federal grant | Department of Health and Human Services · Phase II · IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | $1,371,030 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Novel CRAC Channel Therapeutic for the Treatment of Primary Hyperhidrosis | $245,256 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $1,276,596 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Novel Calcium Channel Therapeutic for the Treatment of Asthma | $352,030 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $1,223,378 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder | $319,991 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder | $319,991 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase II · IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | $502,010 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder | $1,401,740 | |
| Federal grant | Department of Health and Human Services · Phase II · Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis | $999,997 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Novel Calcium Channel Therapeutic for Dystrophinopathies | $306,872 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder | $1,097,854 | |
| Federal grant | Department of Health and Human Services · Phase II · Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis | $999,997 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1387 | Mycosynthetix, Inc. | — | — |
| 1388 | SELSYM BIOTECH INC | — | — |
| 1389 | NAWGEN, LLC | — | — |
| 1390 | VIVREON BIOSCIENCES LLC | — | — |
| 1391 | GROVE BIOPHARMA, INC. | — | — |
| 1392 | CYNVEC, LLC | — | $500K |
| 1393 | Infinite Elements, Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Modulators of CA2+ Release-Activated CA2+ (CRAC) Channels and Pharmaceutical Uses Thereofgranted
- Modulators Of CA2+ Release-activated CA2+ (crac) Channels And Pharmaceutical Uses Thereofapplication
- Modulators Of CA2+ Release-activated CA2+ (crac) Channels And Pharmaceutical Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.